跳到正文
BioPharm International·· 19 天前AI 评分70

FDA发布细胞与基因治疗产品效价保证最终指南,取代2011年效价检测指南

FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies

AI 导读

FDA于2026年11月2日发布《细胞与基因治疗产品效价保证》最终指南,取代2011年的细胞与基因治疗产品效价检测指南。指南建议从IND申报、BLA批准到上市后验证的全过程实施基于科学与风险的效价保证策略,并针对短效期产品、病毒载体基因治疗和患者个体化治疗给出专门考虑。

正文 · 原文

Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.

FDA issued final guidance on November 2, 2026, recommending that manufacturers of cellular and gene therapy (CGT) products implement a science- and risk-based Potency Assurance Strategy across a product's lifecycle.¹ The guidance, Potency Assurance for Cellular and Gene Therapy Products, replaces the FDA's 2011 potency testing guidance for CGT products. It applies to treatments for serious and often life-threatening conditions.¹

Key facts

  • Agency: FDA (CBER)
  • Guidance: Potency Assurance for Cellular and Gene Therapy Products (final)
  • Issue date: November 2, 2026
  • Supersedes: 2011 Potency Tests for Cellular and Gene Therapy Products guidance
  • Draft issued: December 2023 (docket FDA-2023-D-4299)
  • Scope: IND through BLA approval and postmarket verification
  • Special topics: short shelf lives, viral vectors, patient-specific therapies
  • Next step: FDA webinar on December 10, 2026

"Patients who receive cellular and gene therapies are often battling serious or life-threatening conditions, such as cancers and rare diseases, and they deserve the assurance that the product administered to them will perform as intended," said Karim Mikhail, BPharm, MS, director of the Center for Biologics Evaluation and Research (CBER) at FDA, in an agency press release.¹

What does the final guidance recommend?

Under the Potency Assurance Strategy, manufacturers are guided to test and verify, before a product reaches a patient, that every batch meets a defined potency standard for its intended therapeutic effect.¹ By law, manufacturers must verify that their products work as intended from approval through postapproval monitoring. The guidance presents FDA's current thinking on how to meet that requirement.¹

The recommendations are flexible and risk-based. They are intended to integrate potency considerations at every stage, from early-phase investigational new drug (IND) submissions through biologics license application (BLA) approval and continued postmarket verification.¹ Key topics include controls for variability in raw materials, testing during manufacturing, and laboratory tests that confirm each batch is biologically active in a way that matches its intended therapeutic effect.¹

The guidance also addresses specialized considerations for products with short shelf lives, viral vector gene therapies, and patient-specific therapies.¹ FDA also plans to host a webinar on December 10, 2026, to help stakeholders understand and implement the guidance.¹

How did the guidance develop?

FDA issued the guidance in draft form in December 2023 under docket FDA-2023-D-4299.² The draft described a risk-based approach to assuring potency throughout the product lifecycle. That approach included progressive potency strategies for investigational products and lot-release testing for licensed products. The draft also stated that the final version would supersede the January 2011 guidance, Potency Tests for Cellular and Gene Therapy Products.²

How does it relate to other recent CGT guidance?

The potency guidance follows other recent FDA actions on individualized CGT products. On October 27, 2026, the agency issued the draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management. The draft outlines how sponsors can structure a single BLA for genome editing products tailored to each patient's genetic variant.³ It introduced the Individualized Feature Space (IFS), a set of predefined boundaries within which new patient-specific variants could be added to an approved BLA using in vitro data rather than new clinical trials.³ Comments on that draft are due by November 27, 2026.³

Both documents address products made for individual patients. The potency guidance includes specialized considerations for patient-specific therapies. The genome editing draft relies on assays showing adequate safety and activity for each new variant within the IFS.¹,³

What are the limitations?

FDA guidance documents represent the agency's current thinking and are not legally binding. How the FDA applies the flexible, risk-based recommendations will depend on the product and may be clarified further through the December webinar and individual sponsor interactions. The announcement did not detail which recommendations changed from the 2023 draft, and the genome editing guidance remains in draft form.

References

  1. FDA. FDA provides clarity to support cell and gene therapy development and quality. Press release. Published November 2, 2026. Accessed November 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality
  2. FDA. Potency assurance for cellular and gene therapy products; draft guidance for industry; availability. Fed Regist. 2023;88(248):89707-89709. Published December 28, 2023. Accessed November 3, 2026. https://www.govinfo.gov/content/pkg/FR-2023-12-28/html/2023-28596.htm
  3. US Department of Health and Human Services. FDA and CMS announce new steps to advance gene therapies and expand access for patients with rare diseases. Press release. Published October 27, 2026. Accessed November 3, 2026. https://www.hhs.gov/press-room/fda-cms-advance-gene-therapies-rare-diseases-patient-access.html

Related to this article

Human Respiratory System Lungs Anatomy | Image credit: © magicmine - © magicmine - stock.adobe.com

November 2nd, 2026

Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.

Read more

Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma

October 30th, 2026

Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.

Read more

fda on paper texture | Image credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com

October 29th, 2026

The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.

Read more

Cancer cells forming a solid tumor mass, with detailed cell structure and environment | Image credit: © Ummeya - © Ummeya - stock.adobe.com

November 2nd, 2026

CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.

Read more

3D Rendering of Antibody Drug Conjugate Molecules - ADC - with cytotoxic payload | Image credit: © Alpha Tauri 3D - © Alpha Tauri 3D - stock.adobe.com

October 30th, 2026

Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.

Read more

Sick Young Woman Feeling Bad Suffering From Throat Pain, Sore Throat ,Painful Swallowing , Health Concept. | Image credit: © anut21ng Stock - © anut21ng Stock - adobe.stock.com

October 28th, 2026

All 9 patients treated with BB-301 gene therapy met formal response criteria for improved swallowing in an ongoing OPMD trial.

Read more

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image credit: © LASZLO - © LASZLO - stock.adobe.com

October 28th, 2026

Etentamig cut the risk of progression or death by 60% vs standard therapies in the phase 3 CERVINO trial of triple-class exposed myeloma.

Read more

Collage of many X-rays in very good quality. | Image credit: © itsmejust - © itsmejust - stock.adobe.com

October 27th, 2026

Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.

Read more

来源:BioPharm International · biopharminternational.com

所属事件

查看事件全部
FDA发布CGT效力保证最终指南,替代2011年指南